Sumitomo Pharma (4506) Q4 2025 earnings summary

Executive summary

• Achieved a significant turnaround in FY2024, returning to profitability with net profit of JPY 23.6 billion after a prior year loss, driven by strong growth in three key U.S. products and structural reforms.

• FY2024 revenue reached JPY 398.8 billion, up 26.8% year-over-year, mainly from North America and one-time revenue from MYFEMBREE® transition.

• Major cost reductions, workforce streamlining, and R&D investment prioritization led to significant decreases in SG&A and R&D expenses.

• Launched "Reboot 2027" strategy to rebuild value creation, focusing on innovation in oncology, regenerative medicine/cell therapy, and CNS pipeline expansion.

• No dividends declared for FY2024 or forecasted for FY2025, with financial recovery prioritized.

Financial highlights

• Revenue: JPY 398.8 billion (+26.8% YoY); Core operating profit: JPY 43.2 billion (vs. -JPY 133.0 billion prior year); Net profit: JPY 23.6 billion (vs. -JPY 314.9 billion prior year).

• SG&A expenses decreased by JPY 68.7 billion to JPY 167.7 billion; R&D expenses fell by JPY 42.4 billion to JPY 48.5 billion.

• Operating cash flow turned positive at JPY 16.5 billion in FY2024, up from negative JPY 241.9 billion in FY2023.

• North America revenue was JPY 251.8 billion, up 58.3% year-over-year; Japan revenue declined 12.9% due to loss of exclusivity for key products.

• Revenue from ORGOVYX, MYFEMBREE, and GEMTESA grew 96.9%, 39%, and 78.6% year-over-year, respectively.

Outlook and guidance

• FY2025 revenue forecast is JPY 355.0 billion, down JPY 43.8 billion, mainly due to transfer of Asian business, loss of exclusivity for APTIOM and Equa/EquMet, and forex assumptions.

• Core operating profit expected at JPY 56.0 billion (+29.8% YoY); net profit forecast at JPY 40.0 billion (+69.2% YoY).

• No dividends planned for FY2025 as financial recovery remains a priority.

• Focus remains on growth of ORGOVYX, MYFEMBREE, and GEMTESA, with ORGOVYX and GEMTESA revenues projected to rise by JPY 19.9 billion and JPY 17.1 billion, respectively.

• Targeting JPY 250 billion in revenue from three key products and maintaining core operating profit above JPY 25 billion after FY2027.